CY1108220T1 - Κρυσταλλικη μορφη γd της υδροχλωρικης ιβαβραδινης, μεθοδος παρασκευης της και φαρμακευτικες συνθεσεις που την περιεχουν - Google Patents

Κρυσταλλικη μορφη γd της υδροχλωρικης ιβαβραδινης, μεθοδος παρασκευης της και φαρμακευτικες συνθεσεις που την περιεχουν

Info

Publication number
CY1108220T1
CY1108220T1 CY20081100784T CY081100784T CY1108220T1 CY 1108220 T1 CY1108220 T1 CY 1108220T1 CY 20081100784 T CY20081100784 T CY 20081100784T CY 081100784 T CY081100784 T CY 081100784T CY 1108220 T1 CY1108220 T1 CY 1108220T1
Authority
CY
Cyprus
Prior art keywords
preparation
pharmaceutical compositions
crystalline form
compositions containing
ivabradine
Prior art date
Application number
CY20081100784T
Other languages
English (en)
Inventor
Stéphane Horvath
Marie-Noëlle Auguste
Gérard DAMIEN
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of CY1108220T1 publication Critical patent/CY1108220T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Seasonings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Κρυσταλλική μορφή γd της υδροχλωρικής ιβαβραδίνης του τύπου (I): η οποία χαρακτηρίζεται από το διάγραμμα της περίθλασης Χ επί σκόνης. Φάρμακα.
CY20081100784T 2005-02-28 2008-07-28 Κρυσταλλικη μορφη γd της υδροχλωρικης ιβαβραδινης, μεθοδος παρασκευης της και φαρμακευτικες συνθεσεις που την περιεχουν CY1108220T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0501990A FR2882556B1 (fr) 2005-02-28 2005-02-28 Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
EP06290327A EP1695709B1 (fr) 2005-02-28 2006-02-28 Forme cristalline gamma-d du chlorhydrate del'ivabradine, son procédé de préparation, et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
CY1108220T1 true CY1108220T1 (el) 2014-02-12

Family

ID=34954879

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100784T CY1108220T1 (el) 2005-02-28 2008-07-28 Κρυσταλλικη μορφη γd της υδροχλωρικης ιβαβραδινης, μεθοδος παρασκευης της και φαρμακευτικες συνθεσεις που την περιεχουν

Country Status (43)

Country Link
US (3) US7361651B2 (el)
EP (1) EP1695709B1 (el)
JP (1) JP4628975B2 (el)
KR (1) KR100827503B1 (el)
CN (1) CN100432057C (el)
AP (1) AP2112A (el)
AR (1) AR056931A1 (el)
AT (1) ATE397933T1 (el)
AU (1) AU2006200855B2 (el)
BR (1) BRPI0600696A (el)
CA (1) CA2537404C (el)
CO (1) CO5770095A1 (el)
CR (1) CR8246A (el)
CU (1) CU23615B7 (el)
CY (1) CY1108220T1 (el)
DE (1) DE602006001411D1 (el)
DK (1) DK1695709T3 (el)
EA (1) EA008532B1 (el)
EC (1) ECSP066376A (el)
ES (1) ES2308688T3 (el)
FR (1) FR2882556B1 (el)
GE (1) GEP20084468B (el)
GT (1) GT200600086A (el)
HK (1) HK1096660A1 (el)
HR (1) HRP20080417T5 (el)
IL (1) IL173960A0 (el)
MA (1) MA28132A1 (el)
ME (2) ME02750B (el)
MY (1) MY157933A (el)
NO (1) NO338482B1 (el)
NZ (1) NZ545579A (el)
PE (1) PE20061070A1 (el)
PL (1) PL1695709T3 (el)
PT (1) PT1695709E (el)
RS (1) RS50600B (el)
SA (1) SA06270041B1 (el)
SG (1) SG125233A1 (el)
SI (1) SI1695709T1 (el)
TW (1) TWI314142B (el)
UA (1) UA81340C2 (el)
UY (1) UY29407A1 (el)
WO (1) WO2006092494A1 (el)
ZA (1) ZA200601760B (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
EP2097383B1 (en) 2006-11-30 2012-02-08 Cadila Healthcare Limited Process for preparation of ivabradine hydrochloride
CN101353325B (zh) * 2007-07-27 2011-11-09 上海优拓医药科技有限公司 稳定型盐酸伊伐布雷定结晶及其制备方法
US8212026B2 (en) 2007-05-30 2012-07-03 Ind-Swift Laboratories Limited Process for the preparation of ivabradine hydrochloride and polymorph thereof
WO2010072409A1 (en) 2008-12-22 2010-07-01 Krka, D. D., Novo Mesto Process for preparation of ivabradine
CN101774969B (zh) 2009-01-13 2012-07-04 江苏恒瑞医药股份有限公司 硫酸伊伐布雷定及其i型结晶的制备方法
EP2902384B1 (en) 2010-02-12 2017-11-08 KRKA, D.D., Novo Mesto Form of ivabradine hydrochloride
HUP1000245A2 (en) 2010-05-07 2011-11-28 Richter Gedeon Nyrt Industrial process for the production ivabradin salts
WO2012025940A1 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Polymorphic form of ivabradine hydrochloride and process for preparation thereof
EP2726462B1 (en) * 2011-08-02 2017-03-22 Sandoz AG Acetone solvate of ivabradine hydrochloride
WO2013064427A1 (en) 2011-11-04 2013-05-10 Synthon Bv A process for making crystalline delta-form of ivabradine hydrochloride
EP2589594A1 (en) 2011-11-04 2013-05-08 Urquima S.A. Ivabradine hydrochloride Form IV
US9120755B2 (en) 2011-11-14 2015-09-01 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
WO2014114341A1 (en) 2013-01-24 2014-07-31 Synthon Bv Process for making ivabradine
CZ305096B6 (cs) 2013-10-02 2015-04-29 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
ES2672472T3 (es) 2013-12-12 2018-06-14 Synthon Bv Composición farmacéutica que comprende ivabradina amorfa
EP2774606B1 (en) 2014-02-14 2019-01-30 Synthon B.V. Pharmaceutical composition comprising ivabradine hydrochloride polymorph IV
CZ305436B6 (cs) 2014-07-10 2015-09-16 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice
TWI598360B (zh) * 2016-12-19 2017-09-11 義守大學 Fsbm重組蛋白及其用途
TR201703066A2 (tr) 2017-02-28 2018-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
EP3366282A1 (en) 2017-02-28 2018-08-29 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
IT202000025312A1 (it) 2020-10-26 2022-04-26 Cambrex Profarmaco Milano S R L Processi per la preparazione di polimorfi di ivabradina hcl

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US534859A (en) * 1895-02-26 Condenser for ice-machines
DE3119874A1 (de) * 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
DE3418270A1 (de) * 1984-05-17 1985-11-21 Dr. Karl Thomae Gmbh, 7950 Biberach Neue aminotetralinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0547151B1 (en) 1990-08-29 2002-11-20 Humanetics Corporation Treatment process for promoting weight loss employing a substituted delta 5-androstene
FR2681862B1 (fr) * 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2818552B1 (fr) 2000-12-26 2003-02-07 Servier Lab Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
NO20060949L (no) 2006-08-29
MY157933A (en) 2016-08-15
TWI314142B (en) 2009-09-01
AR056931A1 (es) 2007-11-07
GEP20084468B (en) 2008-08-25
FR2882556A1 (fr) 2006-09-01
TW200640871A (en) 2006-12-01
CU20060038A7 (es) 2008-06-30
DK1695709T3 (da) 2008-09-29
WO2006092494A1 (fr) 2006-09-08
EA200600323A1 (ru) 2006-08-25
SI1695709T1 (sl) 2008-10-31
FR2882556B1 (fr) 2007-05-04
CN100432057C (zh) 2008-11-12
AU2006200855B2 (en) 2010-12-23
MA28132A1 (fr) 2006-09-01
PL1695709T3 (pl) 2008-10-31
EA008532B1 (ru) 2007-06-29
GT200600086A (es) 2006-11-02
US20090318420A1 (en) 2009-12-24
ECSP066376A (es) 2006-11-16
CR8246A (es) 2008-01-21
JP4628975B2 (ja) 2011-02-09
NO338482B1 (no) 2016-08-22
CA2537404C (fr) 2010-04-13
AU2006200855A1 (en) 2006-09-14
KR20060095503A (ko) 2006-08-31
ME01394B (me) 2013-12-20
ZA200601760B (en) 2008-04-30
AP2112A (en) 2010-03-03
IL173960A0 (en) 2006-07-05
EP1695709A1 (fr) 2006-08-30
ES2308688T3 (es) 2008-12-01
KR100827503B1 (ko) 2008-05-06
UA81340C2 (en) 2007-12-25
CU23615B7 (es) 2011-01-27
PT1695709E (pt) 2008-07-04
US20060194964A1 (en) 2006-08-31
HRP20080417T5 (en) 2008-11-30
SG125233A1 (en) 2006-09-29
DE602006001411D1 (de) 2008-07-24
PE20061070A1 (es) 2006-11-18
CA2537404A1 (fr) 2006-08-28
EP1695709B1 (fr) 2008-06-11
HRP20080417T3 (en) 2008-09-30
CO5770095A1 (es) 2007-06-29
HK1096660A1 (el) 2007-06-08
ME02750B (me) 2010-05-07
RS50600B (sr) 2010-05-07
SA06270041B1 (ar) 2010-03-08
JP2006241157A (ja) 2006-09-14
US20080153804A1 (en) 2008-06-26
ATE397933T1 (de) 2008-07-15
BRPI0600696A (pt) 2007-05-08
UY29407A1 (es) 2006-07-31
US7872001B2 (en) 2011-01-18
US7361651B2 (en) 2008-04-22
AP2006003522A0 (en) 2006-02-28
CN1827601A (zh) 2006-09-06
NZ545579A (en) 2007-01-26

Similar Documents

Publication Publication Date Title
CY1108220T1 (el) Κρυσταλλικη μορφη γd της υδροχλωρικης ιβαβραδινης, μεθοδος παρασκευης της και φαρμακευτικες συνθεσεις που την περιεχουν
CY1109011T1 (el) ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ βd ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΔΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
CY1118196T1 (el) Νεα κρυσταλλικη μορφη vi της αγομελατινης, μεθοδος παρασκευης αυτης και οι φαρμακευτικες συνθεσεις που την περιεχουν
CY1118637T1 (el) Νεα κρυσταλλικη μορφη iii της αγομελατινης, μεθοδος παρασκευης αυτης και οι φαρμακευτικες συνθεσεις που την περιεχουν
EA200600320A1 (ru) γ-КРИСТАЛЛИЧЕСКАЯ ФОРМА ГИДРОХЛОРИДА ИВАБРАДИНА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ ЕЁ СОДЕРЖАТ
EA200601662A1 (ru) δ-КРИСТАЛЛИЧЕСКАЯ ФОРМА ГИДРОХЛОРИДА ИВАБРАДИНА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ ЕЁ СОДЕРЖАТ
EA200600322A1 (ru) β-КРИСТАЛЛИЧЕСКАЯ ФОРМА ГИДРОХЛОРИДА ИВАБРАДИНА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ ЕЁ СОДЕРЖАТ
ECSP066914A (es) FORMA CRISTALINA dd DEL CLORHIDRATO DE LA IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y LAS COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
MY151986A (en) Adamantyl diamide derivatives and uses of same
ATE482194T1 (de) Indolonderivate, verfahren zu deren herstellung und deren anwendungen
CY1117753T1 (el) Κρυσταλλικη μορφη του αλατος αργινινης της περινδοπριλης, μεθοδος παρασκευης της και φαρμακευτικες συνθεσεις οι οποιες την περιεχουν
EA200702589A1 (ru) 2,6-хинолинильные производные, способы их получения и их применение
CY1112960T1 (el) Παραγωγα ουριας, μεθοδοι για την παρασκευη τους και χρησεις αυτων
PL1888514T3 (pl) Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych
EA200800393A1 (ru) Новые соединения-аналоги камптотецина, способ их получения и фармацевтические композиции, которые их содержат
ES2335410T8 (es) Derivados de aminopropanol.
UA89904C2 (ru) β КРИСТАЛЛИЧЕСКАЯ ФОРМА АРГИНИНОВОЙ СОЛИ ПЕРИНДОПРИЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕЕ СОДЕРЖИТ
SI1845780T1 (sl) Uporaba derivatov metilfenidata
WO2006078887A3 (en) Methylphenidate derivatives and uses of them
EA200800392A1 (ru) Новые соединения-аналоги камптотецина, способ их получения и фармацевтические композиции, которые их содержат
DE502006009398D1 (de) Substituierte benzokondensierte cycloheptanon-derivate und deren verwendung zur herstellung von arzneimitteln
UY29855A1 (es) Forma cristalina delta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
CU20060193A7 (es) Procedimiento de preparación de la forma cristalina delta del clorhidrato de la ivabradina y las composiciones farmacéuticas que lo contienen